Business
Oncology Pharma Year End Review and Outlook
Oncology Pharma Year End Review and Outlook.
About this update from Oncology Pharma Inc.
[{"type":"text","content":"SAN FRANCISCO, CA / ACCESSWIRE / December 9, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") and its Chief Executive are pleased to give a year end update and provide an outlook for what to look for in the coming months and year ahead. The Company is proud of the progress it has made this past year including the addition of a renowned Chairman to the Scientific Advisory Board, retaining a PCAOB audit firm, commencing financing and work on drug research and studies with a highly experienced team as further described below. The Company has further signed additional licensing agreements throughout the year that it believes will enhance the growth of the Company. It looks forward to continuing, expanding and accelerating the work in the coming year.Oncology Pharma, Inc. is a pioneering oncology company dedicated to providing the financing and the tools to license, develop, manufacture, and commercialize therapeutics. Over the past several years the Company has assembled a team of executives and advisors with proven multi-disciplinary expertise in the fields of oncology and therapeutics with leadership to identify, negotiate and amalgamate "best in class" research, technologies, therapeutics and delivery mechanisms that are synergistic and collaborative. As stated before, the Company's goal is to create value, reduce costs and increase the speed of regulatory approval and commercialization of effective and safer cancer drugs.Oncology Pharma's strategy centers on progressing its licensed products through initial phases of development and finding the appropriate path to commercial success and value creation for its stakeholders. The Company has specifically chosen during these initial phases to focus on pediatrics and the potential orphan drug designation, for which the Company is currently working towards submitting its first application. The capital outlay is projected to be significantly lower than traditional drug development programs and there is a high need for improved therapies for patients with rare cancers with the potential for Oncology Pharma to positively impact these patients worldwide. It is the Company's position that what it is pursuing is groundbreaking and that the pediatric market has been underserved by big pharma, which may allow for significant developments ...